New combo therapy shows promise for tough brain tumor
NCT ID NCT03743662
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase II trial tests whether adding the immunotherapy drug nivolumab to re-irradiation and bevacizumab can improve outcomes for patients with recurrent glioblastoma, a type of aggressive brain cancer. The study enrolls 39 adults whose tumors have returned after standard treatment and have a specific genetic marker (MGMT methylation). The goal is to see if this combination can extend overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hartford Healthcare (Data Collection)
Hartford, Connecticut, 06102, United States
-
Indiana University (Data Collection Only)
Indianapolis, Indiana, 46202, United States
-
Lehigh Valley Health Network (Data Collection Only)
Allentown, Pennsylvania, 18103, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
University of Vermont Medical Center (Data Collection Only)
Burlington, Vermont, 05401, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (a drug that helps the immune system fight cancer)
What this could lead to
If successful, this could offer a new treatment option for people with recurrent glioblastoma, potentially extending survival.
What could go wrong
This is a small, early-phase trial (39 people) with no control group, so results may not be definitive. The combination therapy also carries risks like immune-related side effects and bleeding from bevacizumab.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.